Oncogenic role of rab escort protein 1 through EGFR and STAT3 pathway

被引:0
作者
Un-Jung Yun
Jee Young Sung
Seog-Yun Park
Sang-Kyu Ye
Jaegal Shim
Jae-Seon Lee
Masahiko Hibi
Young-Ki Bae
Yong-Nyun Kim
机构
[1] Comparative Biomedicine Research Branch,Division of Cancer Biology
[2] National Cancer Center,Department of Pathology
[3] Pediatric Oncology Branch,Department of Pharmacology
[4] National Cancer Center,Department of Molecular Medicine
[5] National Cancer Center,undefined
[6] College of Medicine,undefined
[7] Seoul National University,undefined
[8] College of Medicine,undefined
[9] Inha University,undefined
[10] Bioscience and Biotechnology Center,undefined
[11] Nagoya University,undefined
来源
Cell Death & Disease | 2017年 / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Rab escort protein-1 (REP1) is linked to choroideremia (CHM), an X-linked degenerative disorder caused by mutations of the gene encoding REP1 (CHM). REP1 mutant zebrafish showed excessive cell death throughout the body, including the eyes, indicating that REP1 is critical for cell survival, a hallmark of cancer. In the present study, we found that REP1 is overexpressed in human tumor tissues from cervical, lung, and colorectal cancer patients, whereas it is expressed at relatively low levels in the normal tissue counterparts. REP1 expression was also elevated in A549 lung cancer cells and HT-29 colon cancer cells compared with BEAS-2B normal lung and CCD-18Co normal colon epithelial cells, respectively. Interestingly, short interfering RNA (siRNA)-mediated REP1 knockdown-induced growth inhibition of cancer cell lines via downregulation of EGFR and inactivation of STAT3, but had a negligible effect on normal cell lines. Moreover, overexpression of REP1 in BEAS-2B cells enhanced cell growth and anchorage-independent colony formation with little increase in EGFR level and STAT3 activation. Furthermore, REP1 knockdown effectively reduced tumor growth in a mouse xenograft model via EGFR downregulation and STAT3 inactivation in vivo. These data suggest that REP1 plays an oncogenic role, driving tumorigenicity via EGFR and STAT3 signaling, and is a potential therapeutic target to control cancers.
引用
收藏
页码:e2621 / e2621
相关论文
共 202 条
  • [1] Yarden Y(2012)The ERBB network: at last, cancer therapy meets systems biology Nat Rev Cancer 12 553-563
  • [2] Pines G(2013)Targeting the ERBB family in cancer: couples therapy Nat Rev Cancer 13 663-673
  • [3] Tebbutt N(2010)Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Nat Rev Cancer 10 760-774
  • [4] Pedersen MW(2015)Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma Nat Rev Cancer 15 302-310
  • [5] Johns TG(2013)The quest to overcome resistance to EGFR-targeted therapies in cancer Nat Med 19 1389-1400
  • [6] Pao W(2009)Endocytosis and intracellular trafficking of ErbBs Exp Cell Res 315 683-696
  • [7] Chmielecki J(2008)Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer Histochem Cell Biol 129 563-578
  • [8] Furnari FB(2007)Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling Oncogene 26 6968-6978
  • [9] Cloughesy TF(2014)EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR Oncotarget 5 1265-1278
  • [10] Cavenee WK(2011)Role of Rab GTPases in membrane traffic and cell physiology Physiol Rev 91 119-149